Cardiac role of cyclic-gmp hydrolyzing phosphodiesterase type 5: From experimental models to clinical trials

Research output: Contribution to journalArticle

Abstract

Cyclic guanosine monophosphate (cGMP) and its primary signaling kinase, protein kinase G, play an important role in counterbalancing stress remodeling in the heart. Growing evidence supports a positive impact on a variety of cardiac disease conditions from the suppression of cGMP hydrolysis. The latter is regulated by members of the phosphodiesterase (PDE) superfamily, of which cGMP-selective PDE5 has been best studied. Inhibitors such as sildenafil and tadalafil ameliorate cardiac pressure and volume overload, ischemic injury, and cardiotoxicity. Clinical trials have begun exploring their potential to benefit dilated cardiomyopathy and heart failure with a preserved ejection fraction. This review discusses recent developments in the field, highlighting basic science and clinical studies.

Original languageEnglish (US)
Pages (from-to)192-199
Number of pages8
JournalCurrent Heart Failure Reports
Volume9
Issue number3
DOIs
StatePublished - Sep 1 2012

    Fingerprint

Keywords

  • Cyclic GMP-dependent protein kinase
  • Cyclic guanosine monophosphate
  • CyclicAMP
  • Fibrosis
  • Genetic models
  • Heart failure
  • Human
  • Hypertrophy .Ventricular function
  • Ischemia
  • Mitochondria
  • PDE1
  • PDE2
  • PDE5
  • Phosphodiesterase
  • Preconditioning
  • Protein kinase G
  • RGS2
  • Remodeling
  • Signal transduction
  • Sildenafil
  • TRPC channel
  • Tadalafil
  • Transforming growth factor beta

ASJC Scopus subject areas

  • Emergency Medicine
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this